Gilead Launches Bixlenvo Once-Daily Tablet Option for Adults With HIV

Gilead Sciences, Inc. (Nasdaq: GILD) recently announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who […]